News and reflections from the world of AI

    Aurora mScope partners with Aiforia to Bring Integrated AI and Image Management Systems to Pathologists

    With this integration, pathology departments can utilize Aiforia’s clinical grade, CE-IVD marked AI models or ones built using Aiforia Create, and ...
    Written by Aiforia

    Aiforia makes key advancement towards end-to-end clinical pathology workflow solution with the release of its CE-IVD marked Aiforia® Clinical Suite Viewer

    Aiforia Technologies Plc is thrilled to announce it received CE-IVD marking for the Aiforia® Clinical Suite Viewer, a cloud-based platform enabling a ...
    Written by Aiforia

    Aiforia Technologies Plc appoints Vice President of Sales for Europe

    Aiforia has appointed Tamas Regenyi as Vice President of Sales, Europe. The position will be essential to driving Aiforia’s business strategy in the ...
    Written by Aiforia
    April 28, 2022

    Aiforia aims to set a new industry standard for customer support with the launch of its one of a kind Aiforia Community Platform

    Earlier this week Aiforia Technologies launched the Aiforia Community Platform — one of the only available platforms of this nature, for pathologists and scientists utilizing AI for image analysis software in preclinical and clinical settings. The company’s users, ranging from some of the world’s largest pharmaceutical companies to the world’s top ranked hospitals and medical institutions, now ...
    Written by Aiforia
    April 20, 2022

    Aiforia expands its portfolio of CE-IVD marked clinical pathology solutions with new AI model for breast cancer diagnostics

    Aiforia Technologies Plc, Press Release, 20 April, 2022 at 09.30 a.m. EEST. Aiforia Technologies Plc announces the CE-IVD marking of the Aiforia® Clinical AI Model for Breast Cancer; ER. Adding to its repertoire of CE-IVD marked clinical AI models for cancer diagnostics, the new AI model automates the calculation of estrogen receptors (ER) — a group of proteins present in the majority of breast ...
    Written by Aiforia
    February 15, 2022

    Aiforia signs agreement with South Korean biotech company to augment its novel drug discovery platform with AI

    The two companies announced an agreement to add Aiforia’s artificial intelligence technology to Genuv’s ATRIVIEW® proprietary drug discovery platform, used to screen both existing drugs and new substances for neuroprotective and neuroregenerative effects. ATRIVIEW® was used to discover Genuv’s leading drug candidate, SNR1611, which has shown the ability to restore CNS function in preclinical ...
    Written by Aiforia
    1 2 3 4 5